NVS Articles, Novartis AG - From 05/10/24

MacroGenics Inc (NASDAQ:MGNX) released interim data from the TAMARACK Phase 2 study of vobramitamab duocarmazine (vobra duo). TAMARA...

Researchers at Alphabet Inc’s (NASDAQ:GOOG) (NASDAQ:GOOGL) Google DeepMind have developed AlphaFold 3, an new artificial intelligence (...

The Federal Trade Commission (FTC) is intensifying its efforts to challenge numerous pharmaceutical patent listings, aiming to facilitate...

MorphoSys AG (NASDAQ:MOR) is reportedly facing a burgeoning safety concern surrounding pelabresib, an experimental myelofibrosis treatment. My...

Corporate earnings came to the market’s rescue in the past week, helping to overcome rate fears. As we look ahead to the unfolding week, it r...

GSK Plc (NYSE:GSK) has reportedly taken legal action against Pfizer Inc (NYSE:PFE) and BioNTech SE (NASDAQ:BNTX) in a...

Tuesday, Novartis AG (NYSE:NVS) received FDA approval for its Lutathera (lutetium Lu 177 dotatate / INN: lu...

Shares of Swiss pharma giant Novartis AG (NYSE:NVS) after the company raised its full-year guidance following better-than-expected first-quarter...

The mood on Wall Street turned tentative on Tuesday as investors awaited earnings reports from the “Magnificent 7,” companies that fuel...

The mood on Wall Street turned tentative on Tuesday as investors awaited earnings reports from the “Magnificent 7,” companies that fuel...